REGISTERED NUMBER: 13160464 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31 January 2025

for

HEALTHCARE INNOVATION CONSORTIUM LTD

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

Directors:

H B Stollar

H Stollar

Registered office:

117 Chestergate

Macclesfield

Cheshire

SK11 6DP

Registered number:

13160464 (England and Wales)

Accountants:

S&W Partners (Manchester) Limited

Accountants

Northern Assurance Buildings

9-21 Princess Street

Manchester

M2 4DN

Fixed assets

Tangible assets

5

29,293

37,928

Current assets

Debtors

6

134,234

247,649

Cash at bank

173,494

93,371

307,728

341,020

Creditors

Amounts falling due within one year

7

133,251

209,484

Net current assets

174,477

131,536

Total assets less current liabilities

203,770

169,464

Creditors

Amounts falling due after more than one year

8

126,635

-

Net assets

77,135

169,464

Capital and reserves

Called up share capital

9

3

3

Retained earnings

77,132

169,461

Shareholders' funds

77,135

169,464

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 October 2025 and were signed on its behalf by:

H B Stollar - Director

1.	Statutory information

Healthcare Innovation Consortium Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3.	Accounting policies

Basis of preparing the financial statements

The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

4.	Employees and directors

The average number of employees during the year was 10 (2024 - 10 ) .

5.	Tangible fixed assets

Fixtures

Plant and

and

Motor

machinery

fittings

vehicles

Totals

£

£

£

£

Cost

At 1 February 2024

4,057

983

40,705

45,745

Additions

915

-

-

915

At 31 January 2025

4,972

983

40,705

46,660

Depreciation

At 1 February 2024

1,738

143

5,936

7,817

Charge for year

648

210

8,692

9,550

At 31 January 2025

2,386

353

14,628

17,367

Net book value

At 31 January 2025

2,586

630

26,077

29,293

At 31 January 2024

2,319

840

34,769

37,928

6.

Debtors: amounts falling due within one year

2025

2024

£

£

Trade debtors

81,690

247,649

Other debtors

52,544

-

134,234

247,649

7.

Creditors: amounts falling due within one year

2025

2024

£

£

Bank loans and overdrafts

73,365

-

Trade creditors

24,154

22,959

Taxation and social security

34,098

90,433

Other creditors

1,634

96,092

133,251

209,484

8.

Creditors: amounts falling due after more than one year

2025

2024

£

£

Bank loans

126,635

-

9.	Called up share capital

Allotted, issued and fully paid:

Number:

Class:

Nominal

2025

2024

value:

£

£

1

Ordinary

1

1

1

1

A Ordinary

1

1

1

1

C Ordinary

1

1

1

3

3

10.	Other financial commitments

At the year end the company had commitments of £58,500 (2024 £76,500) in respect of operating lease agreements.

11.	Director's advances, credits and guarantees

The director operates a current account with the company which comprises advances of £107,389 (2024 - £72,934 and credits of £35,500 (2024 - 59,002). At the year end the amount due to the company was £41,662 (2024 - £30,227 owed to the director).